378 related articles for article (PubMed ID: 25089351)
1. Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration.
Rezende FA; Lapalme E; Qian CX; Smith LE; SanGiovanni JP; Sapieha P
Am J Ophthalmol; 2014 Nov; 158(5):1071-78. PubMed ID: 25089351
[TBL] [Abstract][Full Text] [Related]
2. VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
Krishnan R; Arora R; De Salvo G; Stinghe A; Severn PS; Pal B; Goverdhan S
Retina; 2015 Sep; 35(9):1750-6. PubMed ID: 26237240
[TBL] [Abstract][Full Text] [Related]
3. Anti-VEGF-refractory exudative age-related macular degeneration: differential response according to features on optical coherence tomography.
Shin JY; Woo SJ; Ahn J; Park KH
Korean J Ophthalmol; 2013 Dec; 27(6):425-32. PubMed ID: 24311928
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor.
Kim KH; Kim JH; Chang YS; Lee TG; Kim JW; Lew YJ
Korean J Ophthalmol; 2015 Oct; 29(5):315-24. PubMed ID: 26457037
[TBL] [Abstract][Full Text] [Related]
5. Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration.
Kanadani TCM; Dos Reis Veloso CE; Dorairaj S; Nehemy MB
Ophthalmic Res; 2017; 58(1):18-26. PubMed ID: 28301850
[TBL] [Abstract][Full Text] [Related]
6. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.
Peden MC; Suñer IJ; Hammer ME; Grizzard WS
Ophthalmology; 2015 Apr; 122(4):803-8. PubMed ID: 25596618
[TBL] [Abstract][Full Text] [Related]
8. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
Montero JA; Ruiz-Moreno JM; Sanchis-Merino E; Perez-Martin S
Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
[TBL] [Abstract][Full Text] [Related]
9. The Timing of Large Submacular Hemorrhage Secondary to Age-Related Macular Degeneration Relative to Anti-VEGF Therapy.
Matsunaga DR; Su D; Sioufi K; Obeid A; Wibbelsman T; Ho AC; Regillo CD
Ophthalmol Retina; 2021 Apr; 5(4):342-347. PubMed ID: 32763426
[TBL] [Abstract][Full Text] [Related]
10. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
[TBL] [Abstract][Full Text] [Related]
11. A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis.
Singh RP; Srivastava S; Ehlers JP; Bedi R; Schachat AP; Kaiser PK
Br J Ophthalmol; 2014 Jun; 98 Suppl 1(Suppl 1):i22-27. PubMed ID: 24836866
[TBL] [Abstract][Full Text] [Related]
12. Subfoveal Choroidal Thickness in Eyes with Neovascular Age-Related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents.
Kanadani TCM; Veloso CE; Nehemy MB
Ophthalmologica; 2018; 240(4):200-207. PubMed ID: 29768266
[TBL] [Abstract][Full Text] [Related]
13. RATES OF EXUDATIVE RECURRENCE FOR EYES WITH INACTIVATED WET AGE-RELATED MACULAR DEGENERATION ON 12-WEEK INTERVAL DOSING WITH BEVACIZUMAB THERAPY.
Hwang RY; Santos D; Oliver SCN
Retina; 2020 Apr; 40(4):679-685. PubMed ID: 30649077
[TBL] [Abstract][Full Text] [Related]
14. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
[TBL] [Abstract][Full Text] [Related]
15. Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study.
Holz FG; Dugel PU; Weissgerber G; Hamilton R; Silva R; Bandello F; Larsen M; Weichselberger A; Wenzel A; Schmidt A; Escher D; Sararols L; Souied E
Ophthalmology; 2016 May; 123(5):1080-9. PubMed ID: 26906165
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study.
Lim JY; Lee SY; Kim JG; Lee JY; Chung H; Yoon YH
Acta Ophthalmol; 2012 Feb; 90(1):61-7. PubMed ID: 20337606
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Factors and Long-term Surgical Outcomes for Exudative Age-related Macular Degeneration with Breakthrough Vitreous Hemorrhage.
Kim TY; Kang HG; Choi EY; Koh HJ; Kim SS; Lee JH; Kim M; Byeon SH; Lee CS
Korean J Ophthalmol; 2020 Aug; 34(4):281-289. PubMed ID: 32783420
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Epiretinal Membrane in Neovascular Age-Related Macular Degeneration Treatment: A Spectral-Domain Optical Coherence Tomography Study.
Chatziralli I; Stavrakas P; Theodossiadis G; Ananikas K; Dimitriou E; Theodossiadis P
Semin Ophthalmol; 2018; 33(5):651-656. PubMed ID: 29115893
[TBL] [Abstract][Full Text] [Related]
19. Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration.
Boltz A; Ruiß M; Jonas JB; Tao Y; Rensch F; Weger M; Garhöfer G; Frantal S; El-Shabrawi Y; Schmetterer L
Ophthalmology; 2012 Aug; 119(8):1615-20. PubMed ID: 22521084
[TBL] [Abstract][Full Text] [Related]
20. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
Brown DM; Chen E; Mariani A; Major JC;
Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
